Prima BioMed to Present at the 15th Annual BIO CEO & Investor Conference

Prima BioMed to Present at the 15th Annual BIO CEO & Investor Conference 
SYDNEY, AUSTRALIA -- (Marketwire) -- 01/28/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the
Company") has announced today that Matthew Lehman, its Chief
Executive Officer, will present at the 15th Annual BIO CEO & Investor
Conference on Tuesday, 12 February 2013 at 11:30am Eastern US Time in
New York, NY. Mr. Lehman will provide an overview of the Company and
its corporate activities.  
The presentation will be a live audio webcast and may be accessed by
visiting Prima BioMed's website at
http://www.primabiomed.com.au/investor/presentations.php. A replay of
the webcast will be available for 90 days following the presentation. 
About Prima BioMed
 Prima BioMed is a globally active biotechnology
company. As a leader in personalized bio-therapeutic products for
cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to
maximize value to shareholders. Prima's lead product is CVac(TM), an
autologous dendritic cell product currently in clinical trials for
ovarian cancer patients who are in remission. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd. 
+1 (919) 710-9061
jessica.brown@primabiomed.com.au  
Australia Investor/Media:
Mr. James Moses
Mandate Corporate 
+61 (0) 420 991 574
james@mandatecorporate.com.au  
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
amuehlhaus@edicto.de 
 
 
Press spacebar to pause and continue. Press esc to stop.